The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

RemeGen's disitamab vedotin with Junshi Pharma's Loqtorzi beat standard chemotherapy in first-line HER2-expressing metastatic urothelial cancer.

In a Phase III trial, sacituzumab tirumotecan outperformed chemo in previously treated EGFR-mutant NSCLC patients, results presented at the ESMO Congress show.

NEW YORK – Taysha Gene Therapies has regained full rights to its lead program, TSHA-102, for Rett syndrome after an option agreement with Astellas expired.

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.

As Novartis moves ahead plans to expand Pluvicto's use based on the PSMAddition trial, experts urge for greater use of ...

Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.

The HER2-targeted ADC showed clear benefits over Roche's Kadcyla in the adjuvant setting, and promising activity versus standard neoadjuvant therapy.

In light of new data at ESMO, researchers debated whether HER2-targeted tyrosine kinase inhibitors or antibody-drug conjugates might be better as initial treatment.

Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.